Group 1 - The core viewpoint of the article is that Sichuan Shuangma is actively involved in the biopharmaceutical sector, focusing on the incubation of innovative drugs through direct investment and incubator platforms [2] - The company has concentrated its efforts on several disease areas, including oncology, autoimmune diseases, metabolic disorders, and neurological diseases, and is developing a number of early-stage innovative drug enterprises with internationally competitive product data [2] - Sichuan Shuangma employs a systematic and platform-based incubation model to promote the transformation of research results into marketable products [2]